The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Sarcopenic obesity and myosteatosis are associated with higher mortality in patients with cirrhosis: Sarcopenic obesity and myosteatosis in cirrhosis
Open accessAbstract
BACKGROUND AND AIMS: Obesity is frequently associated with cirrhosis, and cirrhotic patients may develop simultaneous loss of skeletal muscle and gain of adipose tissue, culminating in the condition of sarcopenic obesity. Additionally, muscle depletion is characterized by both a reduction in muscle size and increased proportion of muscular fat, termed myosteatosis. In this study, we aimed to establish the frequency and clinical significance of sarcopenia, sarcopenic obesity and myosteatosis in cirrhotic patients. METHODS: We analysed 678 patients with cirrhosis. Sarcopenia, sarcopenic obesity and myosteatosis were analysed by CT scan using the third lumbar vertebrae skeletal muscle and attenuation indexes, using previously validated gender-and body mass index-specific cutoffs. RESULTS: Patients were predominately men (n = 457, 67%), and cirrhosis aetiology was hepatitis C virus in 269 patients (40%), alcohol in 153 (23%), non-alcoholic steatohepatitis/cryptogenic in 96 (14%), autoimmune liver disease in 55 (8%), hepatitis B virus in 43 (6%), and others in 5 patients (1%). Sarcopenia was present in 292 (43%), 135 had sarcopenic obesity (20%) and 353 had myosteatosis (52%). Patients with sarcopenia (22 ± 3 vs. 95 ± 22 months, P < 0.001), sarcopenic obesity (22 ± 3 vs. 95 ± 22 months, P < 0.001), and myosteatosis (28 ± 5 vs. 95 ± 22 months, P < 0.001) had worse median survival than patients without muscular abnormalities. By multivariate Cox regression analysis, both sarcopenia [hazard ratio (HR) 2.00, 95% confidence interval (CI) 1.44-2.77, P < 0.001], and myosteatosis (HR 1.42, 95% CI 1.02-1.07, P = 0.04) were associated with mortality. CONCLUSIONS: Sarcopenia, sarcopenic obesity and myosteatosis are often present in patients with cirrhosis, and sarcopenia and myosteatosis are independently associated with a higher long-term mortality in cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Obesity and sarcopenic obesity are risk factors for clinical decompensation and worsen prognosis.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [450]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Sarcopenic obesity, the state of decreased muscle mass in the setting of increased fat mass, occurs mainly in MASH-related cirrhosis and is found in 20 -35% of individuals with cirrhosis pre-and-post liver transplant.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [450]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global nutrition transition and the pandemic of obesity in developing countries
Popkin, B. M., Adair, L. S., & Ng, S. W. (2012) · Nutrition Reviews · doi:10.1111/j.1753-4887.2011.00456.x · Cited by 4,313
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Martin, L., Birdsell, L., Macdonald, N., Reiman, T., Clandinin, M. T., McCargar, L. J., Murphy, R. A., Ghosh, S., Sawyer, M. B., & Baracos, V. E. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2722 · Cited by 2,747
Mourtzakis, M., Prado, C. M. M., Lieffers, J. R., Reiman, T., McCargar, L. J., & Baracos, V. E. (2008) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h08-075 · Cited by 2,224
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107
Ogden, C. L., Yanovski, S. Z., Carroll, M. D., & Flegal, K. M. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.052 · Cited by 1,561
Mitsiopoulos, N., Baumgartner, R. N., Heymsfield, S. B., Lyons, W., Gallagher, D., & Ross, R. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.1.115 · Cited by 1,522
Visser, M., Goodpaster, B. H., Kritchevsky, S. B., Newman, A. B., Nevitt, M., Rubin, S. M., Simonsick, E. M., Harris, T. B., & Study, F. T. H. A. (2005) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/60.3.324 · Cited by 1,403
Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis
Montaño‐Loza, A. J., Meza–Junco, J., Prado, C. M. M., Lieffers, J. R. L., Baracos, V. E., Bain, V. G., & Sawyer, M. B. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.028 · Cited by 825
Sarcopenia: etiology, clinical consequences, intervention, and assessment
Lang, T., Streeper, T., Cawthon, P. M., Baldwin, K., Taaffe, D. R., & Harris, T. B. (2009) · Osteoporosis International · doi:10.1007/s00198-009-1059-y · Cited by 815
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–513 of 513
Endocrinological Aspects of Sarcopenia
Minnetti, M., Poggiogalle, E., Vincenzo, O. D., Migliaccio, S., & Donini, L. M. (2026) · Endocrinology · doi:10.1007/978-3-030-71067-5_22-1
Shen, L., Wu, D., Lai, J., He, G., Li, G., 潘君勇, Huang, M., Zhang, C., Wang, L., Tian, Y., et al. (2026) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2026.111922
Pang, Y., Li, N., Ding, Y., Hou, S., Liu, J. J., Liu, X., Liu, E., & Chen, X. (2026) · Animal Models and Experimental Medicine · doi:10.1002/ame2.70241
MASLD and Pancreatic Diseases: From Shared Mechanisms to Clinical Implications and Future Directions
Rivera‐Esteban, J., Agudo, B., Patrizi, B., Manzur, A., de la Iglesia, D., Valverde-Salazar, V., Ferris, N. G., Esteban, C., Santos, E., Pons, F., et al. (2026) · Nutrients · doi:10.3390/nu18152480
The dynamic spectrum of steatotic liver disease: the global perspective
Younossi, Z. M., Zelber‐Sagi, S., Kalligeros, M., Wajcman, D. I., Henry, L. L., Grinshpan, L. S., Israelsen, M. E., Díaz, L. A., Fan, J., Arrese, M. A., et al. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01235-3
Bromfield, B. B., Ruiz‐Margáin, A., Kulik, L., & Duarte‐Rojo, A. (2026) · Current Hepatology Reports · doi:10.1007/s11901-026-00745-7
Boateng, S., Zahrawi, F., Ameyaw, P. A., Zai, M. J., Khosousi, M., Khungar, V., & Banini, B. A. (2026) · Livers · doi:10.3390/livers6040081
Forsgren, M. F., Sjögren, D., Stjernman, H., Nasr, P., Balkhed, W., Cederborg, A., Holmberg, M., Bartholomä, W. C., Jönsson, C., Lundberg, P., et al. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.102031
Neue Therapieansätze bei MASH: Mechanismen und klinisches Potenzial
Barton, A., & Schattenberg, J. M. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2894-7716
Aghazada, F., Kaya, E. M., Kapucu, H. B., Arslan, M. F., Dablan, A., Akkaş, B. E., & KAYA, M. (2026) · Research Square · doi:10.21203/rs.3.rs-11020553/v1
EASL-EASD-EASO guidance on the use of resmetirom and semaglutide as MASH-targeted therapy
Tacke, F., Horn, P., Wong, V. W. S., Ratziu, V., Bugianesi, E., Francque, S., Zelber‐Sagi, S., Caussy, C., Roden, M., Gastaldelli, A., et al. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.08.028
MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management
Krzewiński, H., Wątroba, O., & Koza, J. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197540
Masetti, C., Pugliese, N., Lofino, L., Colapietro, F., Ceriani, R., Lleò, A., Poretti, D., Pedicini, V., Nicola, S. D., Torzilli, G., et al. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.10225845
Metadata
- Authors
- Montano-Loza, A. J., Angulo, P., Meza-Junco, J., Prado, C. M. M., Sawyer, M. B., Beaumont, C., Esfandiari, N., Ma, M., & Baracos, V. E.
- Affiliations
- Division of Gastroenterology & Liver Unit; University of Alberta Hospital; Edmonton Alberta Canada
- University of Kentucky HealthCare (US)
- Department of Oncology; Cross Cancer Institute; Edmonton Alberta Canada
- University of Alberta (CA)
- Cross Cancer Institute (CA)
- Alberta Hospital Edmonton (CA)
- Venue
- Journal of Cachexia Sarcopenia and Muscle
- Publisher
- Wiley
- Published
- 2015-06-09
- Volume
- 7
- Issue
- 2
- Pages
- 126-135
- ISSN
- 2190-5991 (ISSN-L)
- PMC
- PMC4864157
- OpenAlex
- W1490232555
- Cited by
- 512
- References
- 43
- Citations by year
- 2026: 29 · 2025: 34 · 2024: 67 · 2023: 67 · 2022: 78 · 2021: 53 · 2020: 48 · 2019: 53 · 2018: 48 · 2017: 26 · 2016: 4 · 2015: 3
- FWCI
- 19.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Cachexia Sarcopenia and Muscle (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- UKnowledge (University of Kentucky) (submittedVersion, cc-by-nc-nd)
- Funders
- American College of Gastroenterology Institute 2011
- Topics
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Keywords
- myosteatosis, sarcopenia, liver cirrhosis, mortality, skeletal muscle, hepatic steatosis, prognostic factors, hepatitis C, alcoholic cirrhosis, nonalcoholic steatohepatitis, autoimmune liver disease, hepatitis B, body mass index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
